Small molecule · Neurology

Carbidopa

Lodosyn
Small moleculePeripheral AADC inhibitor (adjunct to levodopa)

PubChem CID 34359 · 3D model

Drag to rotate. Scroll or pinch to zoom.

Doesn't treat Parkinson's on its own — it stops the body from converting its partner drug, levodopa, into dopamine too early, before it reaches the brain, so more of it gets through.

How it works

Carbidopa doesn't treat Parkinson's disease by itself — its whole job is to protect levodopa, the actual medicine, also on this site. It stops the body from converting levodopa into dopamine too early, before it reaches the brain, since dopamine itself can't cross into the brain but levodopa can. That lets more levodopa arrive where it's needed and cuts down on side effects like nausea along the way.

What it’s used for

Carbidopa is never used on its own to treat Parkinson's — it only works as a partner to levodopa. It's built into combination pills like Sinemet, and a standalone tablet (Lodosyn) exists too, but only to fine-tune a levodopa regimen someone is already taking.

Mechanism
Peripheral AADC (adjunct to levodopa)
Drug class
Therapeutic area
Neurology

Related drugs

Also available combined as